SCHEMBL2770023

SCHEMBL2770023

COC(=O)Cc1c(C)c(S(=O)(=O)Cc2ccc(Cl)cc2)n2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.42
HCRTR2 O43614 3/20 0.42
MAPK1 P28482 3/20 0.40
KDM4E B2RXH2 3/20 0.40
ALOX15 P16050 2/20 0.40
TSHR P16473 2/20 0.40
HSD17B10 Q99714 2/20 0.40
POLB P06746 1/20 0.40
CASP1 P29466 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
DRD2 P14416 1/20 0.39
TBXA2R P21731 1/20 0.39
HTT P42858 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HAT1 O14929 2/20 0.38
EP300 Q09472 2/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13800545 0.88 HCRTR2 (0.46) HCRTR1HCRTR2MAPK1TSHRHTT
SCHEMBL2770449 0.80 ACLY (0.44) MAPK1KDM4EALOX15TSHRHSD17B10
SCHEMBL2774077 0.80 POLB (0.38) MAPK1KDM4EALOX15TSHRHSD17B10
SCHEMBL2769429 0.75 EGFR (0.43) MAPK1KDM4EALOX15DRD2TBXA2R
SCHEMBL2588741 0.73 HCRTR2 (0.71) HCRTR1HCRTR2MAPK1KDM4EALOX15
SCHEMBL2770132 0.73 ABCB1 (0.44) TBXA2RALDH1A1PTGS2L3MBTL1
SCHEMBL4636277 0.72 HCRTR1 (0.43) HCRTR1HCRTR2MAPK1KDM4EALOX15
SCHEMBL2586103 0.67 HCRTR2 (0.58) HCRTR1HCRTR2MAPK1KDM4EALOX15
SCHEMBL191324 0.65 CYP4F2 (0.63) MAPK1TSHRPOLBALDH1A1MAPT
SCHEMBL7710724 0.65 HCRTR2 (0.70) HCRTR1HCRTR2MAPK1KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910357-B1 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LTD (GB) 2010-04-14 EP disclosed
US-20090163534-A1 Indolizine Derivatives ARGENTA DISCOVERY LIMITED (GB) 2009-06-25 US disclosed
EP-1910357-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS Argenta Discovery Limited (GB) 2008-04-16 EP disclosed
WO-2006136859-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163534-A1 Indolizine Derivatives HRH4, HRH2, NR1H2 HCRTR1 40/4885HCRTR2 14/4885MAPK1 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.